On December 12, 2024, Novo Nordisk announced that the European Medicines Agency has positively recommended updating the Ozempic® label to include its efficacy in reducing kidney disease progression by 24% and cardiovascular death by 18%. This is significant as it highlights a major advancement in treating chronic kidney disease associated with type 2 diabetes, making Ozempic the first GLP-1 receptor agonist to show such benefits.